Legend Biotech Corporation
LEGN
Peringkat dalam Saham
#4479
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Harga Saham
$18.60
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$3.44B
Perubahan (1 hari)
-6.06%
Perubahan (1 tahun)
-41.80%
Negara
US
Perdagangan Legend Biotech Corporation (LEGN)
Kategori
Healthcare
Margin Operasi untuk Legend Biotech Corporation (LEGN)
Margin Operasi per October 2026 TTM: -4.42%
Menurut laporan keuangan dan harga saham terbaru dari Legend Biotech Corporation, margin operasi saat ini (TTM) adalah -4.42%. Pada akhir 2023, margin operasi perusahaan adalah -154.13%.
Riwayat margin operasi untuk Legend Biotech Corporation dari 2017 hingga 2026
Margin Operasi pada akhir setiap tahun
| Tahun | Margin Operasi | Mengubah |
|---|---|---|
| 2026 (TTM) | -4.42% | -90.86% |
| 2024 | -48.35% | -68.63% |
| 2023 | -154.13% | -60.44% |
| 2022 | -389.58% | -11.00% |
| 2021 | -437.71% | 5.71% |
| 2020 | -414.06% | 81.18% |
| 2019 | -228.54% | 7,225.00% |
| 2018 | -3.12% | -105.34% |
| 2017 | 58.41% | 0.00% |
Margin Operasi untuk perusahaan sejenis atau pesaing
| Perusahaan | Margin Operasi | Perbedaan Margin Operasi | Negara |
|---|---|---|---|
| 38.59% | -108.73% |
US
|
|
| -149.01% | -66.29% |
US
|
|
| 25.57% | -105.79% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -106.52% |
NL
|
Apa itu Margin Operasi perusahaan?
Margin Operasi adalah indikator utama untuk menilai profitabilitas suatu perusahaan. Margin Operasi yang lebih tinggi umumnya lebih baik karena menunjukkan bahwa perusahaan mampu menjual produk atau layanan mereka dengan harga yang jauh lebih tinggi daripada biaya produksinya. Margin Operasi dihitung dengan membagi laba perusahaan dengan pendapatannya.